FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912488281> ?p ?o ?g. }

• W2912488281 endingPage "1123" @default.
• W2912488281 startingPage "1113" @default.
• W2912488281 abstract "Glembatumumab vedotin is an antibody-drug conjugate that produced preliminary clinical activity against advanced melanoma in a phase 1 dose-escalation trial. The objective of the current study was to investigate further the antitumor activity of glembatumumab vedotin at the recommended phase 2 dose in heavily pretreated patients with melanoma.This single-arm, phase 2 study enrolled patients with stage IV melanoma who were refractory to checkpoint inhibition and to B-raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibition (in the presence of a BRAF valine mutation at codon 600). Patients received 1.9 mg/kg glembatumumab vedotin intravenously every 3 weeks until they developed disease progression or intolerance. The primary endpoint was objective response rate (ORR), which was determined according to Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints included progression-free survival (PFS), duration of response, overall survival (OS), safety, and clinical efficacy versus tumor glycoprotein NMB (gpNMB) expression. Tumor expression of gpNMB was assessed using immunohistochemistry.In total, 62 patients received treatment. The ORR was 11% and the median response duration was 6.0 months (95% confidence interval [CI], 4.1 months to not reached). The median PFS was 4.4 months (95% CI, 2.6-5.5 months), and the median OS was 9.0 months (95% CI, 6.1-11.7 months). For patients who developed rash during the first cycle versus those who did not, the ORR was 21% versus 7%, respectively, and there was an overall improvement in PFS (hazard ratio, 0.43; P = .013) and OS (hazard ratio, 0.43; P = .017). The most frequent adverse events were alopecia, neuropathy, rash, fatigue, and neutropenia. With one exception, all evaluable tumors were positive for gpNMB, and 46 of 59 tumors (76%) had 100% gpNMB-positive epithelial cells.Glembatumumab vedotin had modest activity and an acceptable safety profile in patients with advanced melanoma who were refractory to checkpoint inhibitors and MEK/BRAF inhibition. Treatment-related rash may be associated with response." @default.
• W2912488281 created "2019-02-21" @default.
• W2912488281 creator A5004419812 @default.
• W2912488281 creator A5013955755 @default.
• W2912488281 creator A5019015178 @default.
• W2912488281 creator A5022765643 @default.
• W2912488281 creator A5024007442 @default.
• W2912488281 creator A5025067315 @default.
• W2912488281 creator A5028592995 @default.
• W2912488281 creator A5028976895 @default.
• W2912488281 creator A5034245329 @default.
• W2912488281 creator A5041066193 @default.
• W2912488281 creator A5044615683 @default.
• W2912488281 creator A5056507476 @default.
• W2912488281 creator A5063337705 @default.
• W2912488281 creator A5077050764 @default.
• W2912488281 creator A5077196075 @default.
• W2912488281 creator A5085041670 @default.
• W2912488281 creator A5086476244 @default.
• W2912488281 creator A5090769354 @default.
• W2912488281 date "2019-01-28" @default.
• W2912488281 modified "2023-10-05" @default.
• W2912488281 title "A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma" @default.
• W2912488281 cites W1519934593 @default.
• W2912488281 cites W1809627231 @default.
• W2912488281 cites W1969738419 @default.
• W2912488281 cites W1983984116 @default.
• W2912488281 cites W1996602050 @default.
• W2912488281 cites W2005354746 @default.
• W2912488281 cites W2019607817 @default.
• W2912488281 cites W2061648145 @default.
• W2912488281 cites W2071055446 @default.
• W2912488281 cites W2095911832 @default.
• W2912488281 cites W2097914739 @default.
• W2912488281 cites W2099842692 @default.
• W2912488281 cites W2106529185 @default.
• W2912488281 cites W2112121482 @default.
• W2912488281 cites W2118102300 @default.
• W2912488281 cites W2123001989 @default.
• W2912488281 cites W2152897456 @default.
• W2912488281 cites W2156762984 @default.
• W2912488281 cites W2164829453 @default.
• W2912488281 cites W2173303337 @default.
• W2912488281 cites W2173572264 @default.
• W2912488281 cites W2507950939 @default.
• W2912488281 cites W2082248513 @default.
• W2912488281 doi "https://doi.org/10.1002/cncr.31892" @default.
• W2912488281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30690710" @default.
• W2912488281 hasPublicationYear "2019" @default.
• W2912488281 type Work @default.
• W2912488281 sameAs 2912488281 @default.
• W2912488281 citedByCount "45" @default.
• W2912488281 countsByYear W29124882812018 @default.
• W2912488281 countsByYear W29124882812019 @default.
• W2912488281 countsByYear W29124882812020 @default.
• W2912488281 countsByYear W29124882812021 @default.
• W2912488281 countsByYear W29124882812022 @default.
• W2912488281 countsByYear W29124882812023 @default.
• W2912488281 crossrefType "journal-article" @default.
• W2912488281 hasAuthorship W2912488281A5004419812 @default.
• W2912488281 hasAuthorship W2912488281A5013955755 @default.
• W2912488281 hasAuthorship W2912488281A5019015178 @default.
• W2912488281 hasAuthorship W2912488281A5022765643 @default.
• W2912488281 hasAuthorship W2912488281A5024007442 @default.
• W2912488281 hasAuthorship W2912488281A5025067315 @default.
• W2912488281 hasAuthorship W2912488281A5028592995 @default.
• W2912488281 hasAuthorship W2912488281A5028976895 @default.
• W2912488281 hasAuthorship W2912488281A5034245329 @default.
• W2912488281 hasAuthorship W2912488281A5041066193 @default.
• W2912488281 hasAuthorship W2912488281A5044615683 @default.
• W2912488281 hasAuthorship W2912488281A5056507476 @default.
• W2912488281 hasAuthorship W2912488281A5063337705 @default.
• W2912488281 hasAuthorship W2912488281A5077050764 @default.
• W2912488281 hasAuthorship W2912488281A5077196075 @default.
• W2912488281 hasAuthorship W2912488281A5085041670 @default.
• W2912488281 hasAuthorship W2912488281A5086476244 @default.
• W2912488281 hasAuthorship W2912488281A5090769354 @default.
• W2912488281 hasBestOaLocation W29124882811 @default.
• W2912488281 hasConcept C126322002 @default.
• W2912488281 hasConcept C143998085 @default.
• W2912488281 hasConcept C159654299 @default.
• W2912488281 hasConcept C203014093 @default.
• W2912488281 hasConcept C203092338 @default.
• W2912488281 hasConcept C207103383 @default.
• W2912488281 hasConcept C2777325958 @default.
• W2912488281 hasConcept C2777658100 @default.
• W2912488281 hasConcept C2778570526 @default.
• W2912488281 hasConcept C2779984678 @default.
• W2912488281 hasConcept C31760486 @default.
• W2912488281 hasConcept C44249647 @default.
• W2912488281 hasConcept C502942594 @default.
• W2912488281 hasConcept C535046627 @default.
• W2912488281 hasConcept C542903549 @default.
• W2912488281 hasConcept C71924100 @default.
• W2912488281 hasConcept C90924648 @default.
• W2912488281 hasConcept C98274493 @default.
• W2912488281 hasConceptScore W2912488281C126322002 @default.
• W2912488281 hasConceptScore W2912488281C143998085 @default.

• next